2:41 PM
 | 
Jun 16, 2017
 |  BioCentury  |  Finance

Twist's proof points

Why Twist opted for a $60M venture round rather than IPO

Twist Bioscience Corp. is expanding its drug discovery and data storage businesses and ramping up its core DNA synthesis business to build a stronger case for an IPO.

When Twist raised a $61 million series D in January 2016 it was expected to be its final venture round before an IPO. However, CEO Emily Leproust said market demand in two areas that the company had pegged as long-term growth drivers for its DNA synthesis technologies ramped up faster than expected -- namely, data storage and drug discovery (see BioCentury,...

Read the full 437 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >